Browsing: Lucid Diagnostics

PAVmed (NASDAQ: PAVM) announced its Q4 and full-year 2024 financial results, showcasing substantial advancements across its subsidiaries, particularly Lucid Diagnostics and Veris Health.

Lucid Diagnostics (NASDAQ: LUCD) announced robust financial results for the fourth quarter and full year of 2024, highlighting significant growth in EsoGuard test volume and key strategic achievements. The company also provided a business update, emphasizing its progress in commercial coverage and new sales channels.

Lucid Diagnostics (LUCD) has received its first positive commercial insurance coverage policy for its EsoGuard® Esophageal DNA Test from Highmark Blue Cross Blue Shield in New York State. This coverage applies to patients who meet professional society guidelines for testing.

Lucid Diagnostics has achieved a key milestone with its EsoGuard® Esophageal DNA Test securing its first positive commercial insurance coverage through Highmark Blue Cross Blue Shield in New York.

Lucid Diagnostics announces positive coverage policy for EsoGuard® test in New York.